Colorectal cancer, when identified at an early stage, is highly treatable—approximately 90% of patients with stage I disease survive at least five years after diagnosis. In contrast, once the cancer has spread beyond the bowel (metastatic disease), the prognosis worsens considerably, with a 5‑year survival rate of only about 14%.
Earlier observational and preclinical studies raised hope that vitamin D3 supplementation, when combined with standard chemotherapy, might slow disease progression and improve survival in patients with metastatic colorectal cancer. To test this hypothesis more rigorously, the SOLARIS randomized phase III trial was conducted and recently published in JAMA. The study compared high‑dose vitamin D3 against a lower‑dose regimen to see whether the higher dose could extend progression‑free survival.
The results, however, did not show a statistically significant overall survival benefit for the high‑dose group. A notable subgroup finding emerged: patients whose primary tumor was located in the left colon appeared to gain some advantage from the higher dose, but this observation was not enough to change the overall conclusion. In essence, the trial failed to establish a general superiority of high‑dose vitamin D3 over lower doses.
Despite the negative primary outcome, the study has drawn positive reactions from the medical community. Dr. Kimmie Ng, the lead author and a professor at Harvard Medical School, emphasised the value of such findings. Moreover, Dr. Ketan Thanki, a colorectal surgeon not involved in the research, highlighted that so‑called “negative” trials are just as critical—if not more so—than positive ones. Without them, the literature would be biased toward promising results, leading to wasted resources on unpromising avenues and repeated experiments that have already been answered. As Dr. Thanki noted, a well‑conducted negative trial like SOLARIS can settle an open question, steer future research in more productive directions, and offer genuine biological insights.
In summary, while high‑dose vitamin D3 does not appear to offer a blanket survival advantage for metastatic colorectal cancer, the possible left‑sided tumour effect warrants further exploration. More importantly, the trial underscores the scientific value of rigorously reported negative results in guiding clinical decision‑making and resource allocation.
